- 1 Time-restricted eating and exercise training before and during pregnancy for people with
- 2 increased risk of gestational diabetes: the BEFORE THE BEGINNING randomised controlled
- 3 trial
- 4 Sujan MAJ\*, doctoral student<sup>1,2</sup> (0000-0002-5505-3623),
- 5 Skarstad HMS\*, doctoral student<sup>1</sup> (0009-0001-2277-6390),
- 6 Rosvold G, research assistant<sup>1</sup> (0009-0001-3879-8199),
- 7 Fougner SL, associate professor and senior endocrinologist<sup>3,4</sup> (0000-0003-1626-4169),
- 8 Follestad T, associate professor<sup>5</sup> (0000-0002-9686-6452),
- 9 Salvesen KÅ, head of department and professor<sup>2,3</sup> (0000-0002-1788-4063),
- 10 Moholdt T\*\*, research scientist<sup>1,2\*</sup> (0000-0003-1024-8088)
- 11
- <sup>1</sup>Department of Circulation and Medical Imaging, Norwegian University of Science and
   Technology, Trondheim, Norway
- <sup>2</sup>Department of Women's Health, St. Olavs Hospital, Trondheim University hospital,
   Trondheim, Norway
- <sup>3</sup>Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
- <sup>4</sup>Department of Endocrinology, St. Olavs Hospital, Trondheim University hospital,
   Trondheim, Norway
- <sup>5</sup>Department of Public Health and Nursing, Norwegian University of Science and Technology,
- 21 Trondheim, Norway
- 22
- 23 \*Shared first author
- 24 \*\*Correspondence to: Moholdt T, trine.moholdt@ntnu.no
- Postal address: NTNU, Faculty of Medicine and Health Sciences, Department of Circulation
   and Medical Imaging, Postbox 8905, 7491 Trondheim, Norway
- 27 E-mail addresses: MAJS: md.a.j.sujan@ntnu.no, HMSS: hanna.s.skarstad@ntnu.no, GR:
- 28 guro.rosvold@ntnu.no, SLF: stine.fougner@ntnu.no, TF: turid.follestad@ntnu.no, KÅS:
- 29 pepe.salvesen@ntnu.no, TM: trine.moholdt@ntnu.no
- 30
- 31
- 32

00

- 34
- 35
- 36
- 37
- 38
- 39
- 40

## 42 Abstract

43 **Objective** To determine the effect of a pre-pregnancy lifestyle intervention on glucose 44 tolerance in people at higher risk of gestational diabetes mellitus (GDM).

45

46 **Design** Randomised controlled trial.

47

48 **Setting** University hospital in Trondheim, Norway.

- 49
- 50 **Participants** 167 people with at least one risk factor for GDM who contemplated pregnancy. 51

**Intervention** The participants were randomly allocated (1:1) to a lifestyle intervention or a standard care control group. The intervention consisted of exercise training and timerestricted eating, started pre-pregnancy and continued throughout pregnancy. Exercise volume was set using a physical activity metric that translates heart rate into a score (Personal Activity Intelligence, PAI), with the goal of  $\geq$  100 weekly PAI-points. Timerestricted eating involved consuming all energy within  $\leq$  10 hours/day,  $\geq$  5 days per week.

58

59 Main outcome measures 2-hour plasma glucose level in an oral glucose tolerance test
60 (OGTT) in gestational week 28. The primary analysis used an intention-to-treat principle.

61

## 62 Results

63 From 02.10.2020 to 12.05.2023, we included 167 participants: 84 in intervention and 83 in 64 control, out of whom 111 became pregnant (56 in intervention and 55 in control). One 65 participant in the intervention group was excluded from the analysis because of pre-66 pregnancy diabetes. Pregnancy data from one participant in the control group were 67 excluded from the analysis because of twin pregnancy. Time to pregnancy was 112 days (SD 68 105) in the intervention (INT) group and 83 days (SD 69) in the control (CON) group (p =69 .087). The intervention had no significant effect on 2-hour plasma glucose level in an OGTT 70 in gestational week 28 (mean difference, 0.48 mmol/L, 95% confidence interval [CI], -0.05 to 71 1.01, p = .077). There was no evidence of between-group differences in other measures of 72 glycaemic control before or during pregnancy. The intervention did not significantly 73 influence GDM prevalence rates in gestational week 12 (INT 5.5%, CON 5.6%, p = 1.000) or gestational week 28 (INT 14.5%, CON 11.1%, p = .592). In gestational week 28, the 74 75 intervention group had gained less weight (2.0 kg, 95% Cl, -3.3 to -0.8, p = .002) and fat mass 76 (-1.5 kg, 95% Cl, -2.5 to -0.4, p = .008) than the control group. Participants could adhere to 77 the  $\leq$  10-hour eating window and maintain  $\geq$  100 PAI per rolling week pre-pregnancy, but 78 adherence to both intervention components decreased during pregnancy.

79

80 Conclusions

81	A combination of time-restricted eating and exercise training started before and continued				
82	throughout pregnancy had no significant effect on glycaemic control in late pregnancy, but				
83	our findings suggest that the intervention lowered gestational weight and fat mass gain in				
84	people with increased risk of GDM.				
85					
86	Trial registration ClinicalTrials.gov NCT04585581				
87					
88	Abstract word count: 426				
89					
90	Keywords: insulin resistance, time-restricted eating, exercise training, glycaemic control,				
91	diet				
92					
93					
94					
95					
96					
97					
98					

## 99 Introduction

100 Gestational diabetes mellitus (GDM) is defined as hyperglycaemia first diagnosed during 101 pregnancy and affects approximately one out of seven live births globally.(1) Risk factors for 102 GDM include having a high body mass index (BMI) and excessive gestational weight gain, 103 older age, GDM in a previous pregnancy, a family history of diabetes, and non-European 104 ethnicity.(1) Chronic insulin resistance as a result of a complex interplay of these genetic, 105 environmental, and behavioural risk factors aggravates physiological insulin resistance in the 106 second half of pregnancy leading to pancreatic  $\beta$ -cell dysfunction, elevated glucose levels, 107 and eventually GDM.(2) Although the hyperglycaemia usually resolves after delivery, GDM is 108 associated with an increased risk for several adverse consequences later in life, including 109 recurrence of GDM in later pregnancies, type 2 diabetes, metabolic syndrome, and 110 cardiovascular diseases.(3-6) Children of mothers with GDM are at increased risk of cardiac 111 dysfunction at birth, childhood obesity, and future diabetes mellitus, thus continuing the 112 intergenerational cycle of obesity and diabetes.(7–11)

113 Conventional lifestyle recommendations in pregnancy include moderate-intensity 114 exercise for at least 150 minutes per week and a healthy diet.(12) However, many pregnant 115 individuals fail to meet these recommendations and it may be difficult to change lifestyle 116 because of biological changes in pregnancy and due to concerns about the effects on the 117 growing fetus.(13–15) Most clinical trials of lifestyle interventions in pregnancy have 118 initiated the intervention around 16-20 weeks of gestation, leaving a missed window of 119 opportunity to implement lifestyle changes and improve glycaemic control. (16) Since pre-120 pregnancy patterns of physical activity are associated with exercise during pregnancy(17) 121 and pre-pregnancy healthy dietary habits are associated with a lower risk of GDM,(18) the 122 pre-pregnancy period can be a "teachable moment" to make favourable changes that can 123 improve maternal and fetal outcomes. Over the last years, several systematic reviews and 124 meta-analyses have concluded that pre-pregnancy lifestyle interventions are necessary to 125 improve adherence and reduce the risk of GDM and related short- and longer-term adverse 126 outcomes.(19-21) However, the evidence on the specific components of pre-pregnancy 127 interventions and their effectiveness remains scarce. Alternative diet-exercise intervention 128 strategies, such as time-restricted eating (TRE) and high-intensity interval training (HIIT) 129 improve glycaemic control, and cardiometabolic outcomes in non-pregnant people with 130 cardiometabolic disorders.(22–26) The data on the effects of TRE in pregnancy are scarce. 131 We recently showed that it was feasible to consume all energy within maximum 10 h/day 132 for 5 weeks in the second and third trimesters of pregnancy, albeit without effect on the 133 measured cardiometabolic outcomes.(27) However, observational data indicate that longer 134 night-fasting duration is associated with improved fasting glucose in pregnant 135 individuals.(28) Recent publications show that HIIT is safe and enjoyable, as well as relatively 136 easy to adhere to, during pregnancy.(29-31) In the BEFORE THE BEGINNING trial, we 137 hypothesised that combined TRE and exercise training commenced pre-pregnancy and 138 continued throughout pregnancy, would improve maternal glucose tolerance in gestational 139 week 28 in people at increased risk of GDM.

# 141 Methods

## 142 Study design

BEFORE THE BEGINNING was a single-centre randomised controlled trial with two parallel groups: an intervention group and a control group (Figure 1). The trial was undertaken at the Norwegian University of Science and Technology (NTNU) in Trondheim, Norway, in collaboration with the St. Olav's Hospital, Trondheim, Norway. The trial was registered in ClinicalTrials.gov (NCT04585581) on 25.09.2020. A detailed study protocol has been

- 148 published previously.(32)
- 149



#### 150

#### 151 Figure 1. Study design

152 After baseline assessments, the participants were randomly allocated (1:1) to a lifestyle intervention or a 153 standard care control group. The intervention consisted of exercise training and time-restricted eating, started 154 pre-pregnancy, and continued throughout pregnancy. The amount of exercise was set using a heart rate-based 155 physical activity metric (Personal Activity Intelligence, PAI), with the goal of ≥ 100 weekly PAI-points. Time-156 restricted eating involved consuming all energy within  $\leq 10$  hours/day,  $\geq 5$  days per week. Further assessments 157 were performed 8 weeks after baseline in the pre-pregnancy period, and in gestational weeks 12 and 28. 158 Pregnancy and birth outcomes were collected from hospital records after delivery. Neonatal outcomes were 159 assessed within 72 hours after birth and 6-8 weeks after birth. GW = gestational week

160

# 161 **Recruitment and participants**

We advertised the trial on social media, hospital and university websites, local stores, and public places. Moreover, we sent electronic invitations to the trial to all females aged 20-35 years in Trondheim and the surrounding area using information obtained from the national population register. We included females who were 18-39 years old and contemplating

166 pregnancy within the next 6 months, who understood oral and written Norwegian or English

and who had at least one of the following risk factors: BMI  $\geq$  25 kg/m<sup>2</sup>, GDM in a previous 167 pregnancy, close relative with diabetes (parents, siblings, or children with diabetes), fasting 168 169 plasma glucose > 5.3 mmol/L, previous newborn > 4.5 kg, or non-European ethnicity (one or 170 both parents originating from an area outside Europe). Exclusion criteria were ongoing 171 pregnancy, trying to conceive  $\geq$  6 cycles at study entry, known diabetes (type 1 or 2), shift 172 work that included night shifts > 2 days/week, previous hyperemesis, known cardiovascular 173 diseases, high-intensity exercise > 2 times/week in the last 3 months, habitual eating 174 window  $\leq$  12 hours/day, bariatric surgery, or any other reason which according to the 175 researchers made the potential participant ineligible.

176

#### 177 Randomisation and blinding

Baseline assessments were performed before we randomly allocated the participants (1:1) to the intervention or a standard care control group, stratified by GDM in a previous pregnancy (yes/no). The study personnel used WebCRF3, a computer random number generator developed and administered at The Clinical Research Unit (Klinforsk), NTNU/St. Olav's Hospital, Trondheim, Norway to randomly allocate participants using various block sizes. The randomisation sequence was concealed until interventions were assigned. Neither participants nor study personnel were blinded.

185

#### 186 Intervention and adherence

187 The intervention consisted of TRE and exercise training and spanned from inclusion pre-188 pregnancy and throughout pregnancy. We counselled the participants in the intervention 189 group to restrict their daily time-window of energy intake to  $\leq$  10 hours, ending no later 190 than 19:00 hours, for minimum 5 days per week throughout the study period. On the "off" 191 days, the participants could choose their time-window for energy intake. We gave no advice 192 about dietary composition or the amount of energy the participants should consume, and 193 they could consume non-energy drinks outside the time-window.

194 The exercise programme was based on Personal Activity Intelligence (PAI), which is a 195 physical activity metric that translates heart rate during physical activity into a score.(33) 196 We instructed the participants to obtain  $\geq$  100 weekly PAI-points throughout the study 197 period since this amount of physical activity is associated with higher cardiorespiratory fitness and a decreased cardiovascular disease risk.(33,34) High-intensity exercise and thus 198 199 higher heart rates give substantially more PAI-points than low-to-moderate-intensity 200 exercise. The participants in the intervention group wore smartwatches (Amazfit GTS and/or 201 Polar Ignite 2) throughout the study period. These watches shared PAI data with the 202 research team.

The exercise training consisted of endurance exercise with the aim of high intensity and was mainly unsupervised. We provided participants in the intervention group with a brochure suggesting various HIIT sessions to complete at home (Supplementary file 1). The participants were free to choose whether to exercise indoors or outdoors, and if they wanted to use any cardio machines (e.g., treadmill, stationary bike). Once pregnant, we

208 advised the participants to choose between short work-bouts (30 seconds) at high intensity 209 with low-to-moderate intensity periods in-between, or longer work periods with an 210 intensity up to 85% of heart rate maximum. The participants were invited for supervised exercise sessions twice after baseline: after 2 and 4 weeks. Additionally, participants could 211 212 ask for extra support and more supervised sessions at any time during the intervention 213 period. The supervised sessions were undertaken on a treadmill or a stationary bike in our 214 training facility. Participants in the control group received standard care and were asked to 215 continue with their habitual physical activity and dietary intake.

216 We asked all participants to report their daily time-window of energy intake for 4 days (three weekdays and one weekend day) every 8<sup>th</sup> week in a printed study handbook. 217 We categorised participants in the intervention group as adherent to TRE if they reported a 218 219  $\leq$  10-hour time window for energy intake on  $\geq$  2 of these 4 days and as adherent to exercise 220 training if they earned and maintained  $\geq$  75 PAI per rolling week. We sent reminders to all 221 participants via text messages to complete dietary reporting and contacted the participants 222 in the intervention group to offer additional supervised exercise sessions if they were not 223 reaching the PAI target.

224

### 225 Experimental procedures and outcome measures

226 Assessments of the participants were undertaken twice during pre-pregnancy and twice 227 during pregnancy. The first week after allocation to groups consisted of baseline recordings, 228 followed by visits in the laboratory after 8 weeks, and in gestational weeks 12 and 28. 229 Participants who did not become pregnant within 6 months of inclusion were excluded from 230 the study, but their pre-pregnancy data were included in the intention-to-treat analysis 231 (changed from 12 months, see modifications to the protocol after trial commencement). In 232 cases of spontaneous abortions, we adjusted the period to allow the participants to 233 continue in the study by a 4-weeks extension added to the number of weeks the 234 participants were pregnant before abortion.

235

#### 236 *Primary outcome measure*

The primary outcome measure was 2-hour plasma glucose concentration in a 75 g oral glucose tolerance test (OGTT) in gestational week 28. After an overnight fast ( $\geq$  10 hours) and no exercise for  $\geq$  24 hours, the participants consumed a premade drink of 75 g glucose diluted in 250 mL water (Glucosepro, Finnamedical, Finland) within 5 minutes. Using an indwelling catheter, we collected venous blood before the OGTT, with subsequent collections at 30, 60, 90, and 120 minutes after ingestion of glucose.

243

#### 244 Secondary outcome measures

The trial has several secondary outcomes, as specified in the study protocol.(32) Here we report the main secondary maternal cardiometabolic outcomes and will report the remaining secondary outcomes in separate publications. Secondary outcome measures were assessed twice during pre-pregnancy (at baseline and after 8 weeks) and twice during 249 pregnancy (in gestational weeks 12 and 28), if not otherwise specified. Fasting plasma 250 glucose, blood lipids, and glycated haemoglobin (HbA1c) were analysed immediately after 251 blood sampling at St. Olavs Hospital laboratory, following local standardised procedures. 252 GDM was recorded in gestational weeks 12 and 28, and diagnosed according to the WHO 253 2013 criteria: fasting plasma glucose 5.1-6.9 mmol/L and/or 2-hour plasma glucose 8.5-11.0 254 mmol/L after a 75-g glucose load.(35) We measured fasting, 30-minute, and 120-minute 255 insulin concentrations in thawed serum samples with enzyme-linked immunosorbent assay 256 (ELISA, IBL-International, Hamburg, Germany) according to the manufacturer's protocol 257 using a DS2 ELISA processing system (Dynex technologies, Virginia, USA) at the research 258 laboratories at the Department of Circulation and Medical Imaging, NTNU. The area under 259 the curve (AUC) and incremental AUC (iAUC) from glucose concentrations were calculated 260 from venous blood sampling obtained every 30 minutes during the OGTT.(36) We calculated 261 homeostasis model assessment of insulin resistance (HOMA2-IR) and pancreatic beta cell 262 function  $(HOMA2-\beta)$ using the online HOMA2 calculator: 263 https://www.dtu.ox.ac.uk/homacalculator/index.php (37) We also estimated the Insulin 264 Sensitivity Index (ISI<sub>0.120</sub>)(38), insulinogenic index during the first 30 minutes of the 265 OGTT(39), and beta cell function  $(AUC_{ins}/AUC_{glu})(40)$ .

- 266 Weight and body composition were estimated in the morning after overnight fasting 267 using bioelectrical impedance analysis (Inbody 720, Biospace CO, Korea), with participants 268 wearing light clothes and standing barefoot. Additionally, waist circumference was 269 measured using a measuring tape at the level of the navel, in a standing position. We used 270 an automatic blood pressure device (Welch Allyn, Germany) to measure blood pressure and 271 resting heart rate on the participants' left arm after they had rested in a seated position for 272 15 minutes. The average of three measurements taken 1 minute apart is reported. We 273 asked the participants to register their diet in an online food diary (Fatsecret app) intake for 4 days (three weekdays and one weekend day) every 8<sup>th</sup> week. They also completed the 274 International Physical Activity Questionnaire(41) every 8<sup>th</sup> week throughout the study 275 276 period.
- 277

## 278 Modifications to the protocol after trial commencement

279 From November 2022, we started identifying eligible participants using population data from the Norwegian Tax Administration and sending out electronic participant invitations to 280 281 reach a broader target population. Concurrently, we added 'bariatric surgery' and 'any other 282 reason which according to the researchers makes the potential participant ineligible' to 283 undergo either or both interventions (e.g., traumatic foot injury, anorexia/bulimia) as 284 exclusion criteria. From December 2022, we removed 'planned assisted fertilisation with 285 female factor reason' from the exclusion criteria. The changes in the inclusion criteria were 286 made to account for challenges that arose during the screening process. Also in December 287 2022, we changed the maximum time before pregnancy from 12 months to 6 months to 288 allow for the trial to be terminated in time for us to analyse the data within the project 289 period. In March 2023, the required number of total participants was reduced from 260 to

200 based on the revised sample size calculation described below. In June 2023, we changed
from Amazfit GTS (Huami, China) to Polar Ignite 2 (Polar, Finland) smartwatch and from
Zepp and Memento to Polar Flow and Mia app to improve recording of PAI-points.

293

## 294 Sample size

295 The primary outcome measure was 2-hour plasma glucose level in a 75 g OGTT in 296 gestational week 28. We considered a difference between the intervention group and the 297 control group of 1.0 mmol/L as the minimally clinically relevant difference, based on findings 298 from the HAPO study,(7) and have used the observed standard deviation (SD) in 2-hour 299 plasma glucose concentrations during the OGTT from HAPO in the calculations. Sample size 300 calculation for a two-sided t-test to detect a 1.0 mmol/L difference between the groups, 301 using an SD of 1.3, a power of .90, and a significance level of .05, yields 37 participants in 302 each group in gestational week 28. To allow for an expected exclusion from the study due to 303 not conceiving within the study period ( $\sim$ 50%)(42) yielding 74 per group, further drop-out 304 during the study period (10-20%), yielding 93 per group, and to increase statistical power for 305 secondary analyses, we initially wanted to include 260 participants in the trial. However, we 306 concluded participant recruitment after reaching 167 participants, because we at that point 307 had more than 45 participants per group in gestational week 12, which allowed for an 308 anticipated 20% dropout during pregnancy.

309

#### 310 Statistical analysis

311 We analysed data from 166 participants in the intention-to-treat analyses (excluding one 312 participant in the intervention group because of pre-pregnancy diabetes). For the analysis of 313 pregnancy-specific data, we used data obtained from 109 pregnant participants (data 314 obtained during pregnancy from one participant in the control group were excluded from 315 the analysis because of twin pregnancy). We used linear mixed models to estimate 316 differences in primary and secondary continuous outcomes between groups, with time and 317 the interaction between time and group as fixed effects variables, and subject (participant 318 ID) as random effect.(43) Since no systematic baseline differences between the groups are 319 expected in randomised controlled trials, the main effect of group was not included, such 320 that the means at baseline were constrained to be equal in these models. We report 321 estimated effects in the intervention group compared with the control group, with 322 corresponding 95% confidence intervals and p-values. For outcomes obtained only during 323 the pregnancy period (variables using data from the OGTT at gestational week 12 and 28), 324 we included the main effect of group in the linear mixed model.

We checked the normality of residuals by visually inspecting QQ-plots. For variables that were not normally distributed, bias-corrected and accelerated bootstrap confidence intervals (CIs) based on 3000 bootstrap samples were calculated. Additionally, we used Fisher's exact test to compare GDM prevalence in gestational week 12 and chi-square test in gestational week 28, and Student's t-test to compare time to pregnancy between groups. For our primary outcome measure, we considered a *p*-value < .05 to indicate statistically

significant results. For the secondary outcome measures, we used a significance level of .01 to give some protection against fall positives due to multiple comparisons. We also performed pre-specified per-protocol analyses, in which we included only the participants in the intervention group who obtained  $\geq$  75 weekly PAI-points and reported a  $\leq$  10-hour time window for energy intake on  $\geq$  2 out of 4 days in the handbook pre-pregnancy. The statistical analyses were performed using IBM SPSS Statistics 29.0 and STATA MP version 18.

337

## 338 Patient and public involvement

339 In the planning phase, we invited users to discuss the study 1 month before applying to the 340 regional ethical committee for approval. We arranged a 1-hour interactive digital workshop with participant representatives (reproductive-aged females with overweight/obesity) to 341 342 discuss relevant topics or issues related to participation and long-term adherence. Among 343 the topics we discussed were potential barriers to participation in diet-exercise 344 interventions, how to engage participants and keep them engaged, how to increase 345 motivation, use of digital methods to collect exercise- and diet data, and recruitment 346 strategies. Four months after including the first participant, we organised another 347 interactive workshop in which we discussed how to increase participant recruitment and 348 adherence. Based on input from the participant representatives, we established a Facebook 349 group for planning exercise sessions together with other participants. Additionally, we 350 offered supervised exercise training for interested participants at our training facilities via 351 the Facebook group. Participant representatives were not involved in the recruitment 352 process. In February 2023, we had another interactive meeting with participants who 353 completed the study to discuss their views on exercise training during pregnancy and follow-354 up before and during pregnancy.

355

# 356 **Results**

## 357 Participants

We randomised 167 participants (Intervention, n = 84 and Control, n = 83) between October 358 2<sup>nd</sup> 2020 and May 12<sup>th</sup> 2023 (Figure 2). We ended inclusion of new participants when 45 359 participants in each group reached gestational week 12, as per our sample size calculations. 360 361 We excluded one participant in the intervention group because of pre-pregnancy diabetes, 362 leaving data from 166 participants in the intention-to-treat analyses. Within the specified 363 time, 111 participants became pregnant (Intervention, n = 56, Control, n = 55). Pregnancy 364 data from one participant in the control group were excluded from the analysis because of 365 twin pregnancy (Figure 2). Time to pregnancy did not differ significantly between groups, 366 with mean of 112 days (SD 105) in the intervention group and 83 days (SD 69) in the control 367 group (p = .087). Table 1 shows the baseline characteristics of the participants.

- 368
- 369



#### 371 Figure 2. Flowchart of participants

372	* Participants who did not conceive within the specified time were excluded from further participation in the
373	trial, but their pre-pregnancy data were included.

	Control (n = 83)	Intervention (n = 83)
Age, years	30.3 (3.2)	30.2 (3.1)
Weight, kg	81.5 (13.2)	81.1 (16)
Body mass index, kg/m <sup>2</sup>	29.1 (4.5)	29.2 (4.9)
Waist circumference, cm	94.5 (11.8)	93.0 (12.3)
Muscle mass, kg	27.7 (3.6)	27.9 (4.3)
Fat mass, kg	31.7 (9.9)	30.8 (11)
Fat percentage, %	37.9 (7.2)	37.0 (7.6)
Visceral fat area, cm <sup>2</sup>	153 (52)	146 (56)
Systolic blood pressure, mmHg	121 (10)	118 (8)
Diastolic blood pressure, mmHg	79 (7)	79 (6)
Resting heart rate, bpm	72 (11)	71 (11)
HbA1c, mmol/mol	34.3 (3.1)	34.1 (2.8)
Fasting glucose, mmol/L	5.0 (0.4)	4.9 (0.4)
Total cholesterol, mmol/L	4.5 (0.7)	4.6 (0.8)
HDL cholesterol, mmol/L	1.4 (0.3)	1.4 (0.3)
LDL cholesterol, mmol/L	3.0 (0.9)	3.1 (0.8)
Triglycerides, mmol/L	1.0 (0.5)	1.0 (0.5)
Fasting insulin, µIU/mL	19.1 (11.7)	17.1 (10.4)
HOMA2-IR	2.4 (1.4)	2.2 (1.2)
НОМА2-В	168.2 (59.2)	164.9 (69.2)
Parity, total number of births, n (%)		
0	45 (55)	47 (58)
1	30 (37)	30 (37)
2	7 (9)	4 (5)
Education level, n (%)		
Compulsory schooling	0 (0)	1 (1)
Completed upper secondary school	8 (10)	10 (12)
Completed university education, less than 4 years	28 (34)	23 (28)
Completed university education, 4 years or more	46 (56)	47 (58)
Ethnic origin, n (%)		
Europe	74 (89)	72 (87)
Africa and Middle East	3 (4)	1(1)
Asia	4 (5)	6 (7)
North America	1 (1)	1 (1)
Latin America	1 (1)	3 (4)
Reason for inclusion*, n (%)		
Body mass index $\geq$ 25 kg/m <sup>2</sup>	74 (89)	68 (82)
GDM in a previous pregnancy	1 (1)	2 (2)
Family history of diabetes, n	20 (24)	24 (29)
Previous newborn > 4.5 kg <i>, n</i>	1(1)	1 (1)

## 387 Table 1. Baseline characteristics of participants, according to group allocation.

388 Data are presented as means of observed values with standard deviation (SD) or number (n) and percentage

(%) of participants. Missing: number of participants with missing data in each group is 0 to 3 for all variables

390 except for waist circumference, where 5 are missing in the intervention group and 8 in the control group.

HbA1c = Glycated haemoglobin, HDL = High-density lipoprotein cholesterol, LDL = Low-density lipoprotein
 cholesterol, HOMA2-IR = Homeostatic model assessment of insulin resistance, HOMA2-B = Homeostatic model
 assessment of beta cell function, GDM = Gestational diabetes mellitus.

394

407

### 395 **Primary outcome and secondary glycaemic outcomes in pregnancy**

396 There was no statistically significant difference between the intervention and control groups 397 in 2-hour plasma glucose concentrations during a 75 g OGTT (mean difference 0.48 mmol/L, 398 95% CI -0.05 to 1.01, p = .077) in gestational week 28 (Table 2, Figure 3). The intervention 399 did not significantly improve secondary glycaemic outcomes (fasting glucose, fasting insulin, 400 HbA1c, HOMA2-IR, and HOMA2-B) compared with control. No statistically significant 401 between-group differences were found in glycaemic outcomes obtained only during 402 pregnancy (AUC, iAUC, insulinogenic index during the first 30 minutes of OGTT and ISI0.120) 403 (Supplementary file 2). In gestational week 12, three participants in each group fulfilled the 404 criteria for GDM diagnosis (INT 5.5%, CON 5.6%, p = 1.000). The corresponding numbers in 405 gestational week 28 were eight participants (14.5%) in the intervention group and six 406 participants (11.1%) in the control (p = .776) (Supplementary file 2).



408

412

409 Figure 3. Plasma glucose 2 hours after a 75-g oral glucose tolerance test in gestational weeks 12 and 28,
410 according to group. Data are observed means and standard deviations for the intention-to-treat population.
411 The *p*-value was calculated for a test of between-group differences, using a linear mixed model.

#### 413 Secondary outcomes

The estimated mean weight gain in the intervention group in gestational week 28 was 2.0 kg lower (95% CI -3.3 to -0.8, p = .002), and fat mass gain was 1.5 kg lower (95% CI to -2.5 to -0.4, p = .008), than in the control group (Table 2). There was little or no evidence of other between-group differences during pregnancy.

418

Table 2. Intention-to-treat analyses.

420 Data are observed means and standard deviations (SD) at baseline, in pre-pregnancy week 8, gestational week

421 12, and gestational week 28 for *n* participants in each group. Results from linear mixed model analyses are

422 presented as estimated mean difference (Est. effect) in the intervention group compared with the control

423 group, with corresponding 95% confidence interval (CI) and p-values. \*95% CI and p-values are from bias-

424 corrected and accelerated confidence intervals based on bootstrap with 3000 samples, due to non-normally

425 distributed residuals.

		Control ( <i>n</i> = 54)	Intervention ( <i>n</i> = 55)	Difference (intervention - control)		
Outcome	Time	Mean (SD)	Mean (SD)	Est. effect	95% CI	p
Primary outcom	е	1				
2-hour plasma	Gestational week 12	5.8 (1.4)	5.7 (1.3)			
glucose during OGTT. mmol/L	Gestational week 28	6.4 (1.1)	6.7 (1.5)	0.48	-0.05 to 1.01	.077
Secondary outco	omes					
		Control ( <i>n</i> = 83)	Intervention ( <i>n</i> = 83)	Difference (intervention – control)		
Outcome	Time	Mean (SD)	Mean (SD)	Est. effect	95% CI	p
	Baseline	5.0 (0.4)	4.9 (0.4)			
Fasting blood	Pre-pregnancy week 8	5.1 (0.4)	5.0 (0.3)	0.0	-0.2 to 0.1	.392
mmol/L	Gestational week 12	4.5 (0.3)	4.5 (0.3)	0.0	-0.1 to 0.1	.640
	Gestational week 28	4.5 (0.4)	4.5 (0.5)	0.0	-0.1 to 0.2	.427
	Baseline	34.3 (3.1)	34.1 (2.8)			
HbA1c,	Pre-pregnancy week 8	34.5 (3.2)	33.9 (2.5)	-0.4	-1.1 to 0.2	.205
mmol/mol	Gestational week 12	32.7 (2.3)	33.3 (2.4)	0.5	-0.2 to 1.2	.140
	Gestational week 28	32.3 (2.8)	32.0 (3.19	-0.2	-0.9 to 0.5	.516
	Baseline	19.1 (11.7)	17.1 (10.4)			
Fasting insulin,	Pre-pregnancy week 8	19.3 (9.7)	16.3 (8.6)	-2.0	-4.4 to 0.5	.123
µ∣U/mL*	Gestational week 12	12.8 (10.7)	12.3 (9.1)	0.1	-3.8 to 4.0	.960
	Gestational week 28	19.4 (12.2)	18.6 (11.0)	-0.8	-5.0 to 3.4	.716
	Baseline	167.8 (58.9)	164.9 (69.2)			
	Pre-pregnancy week 8	171.2 (59.2)	155.0 (51.6)	-13.8	-30.1 to 2.5	.097
HUMAZ-B	Gestational week 12	153.8 (81.4)	155.8 (68.7)	4.6	-24.1 to 33.2	.755
	Gestational week 28	212.4 (84.9)	205.2 (70.0)	-7.7	-35.1 to 19.6	.579
	Baseline	2.4 (1.4)	2.2 (1.2)			
	Pre-pregnancy week 8	2.4 (1.2)	2.1 (1.1)	-0.2	-0.5 to 0.1	.213
HOMA2-IR*	Gestational week 12	1.6 (1.2)	1.5 (1.1)	0.1	-0.4 to 0.5	.787
	Gestational week 28	2.3 (1.4)	2.3 (1.3)	0.0	-0.5 to 0.5	.878
	Baseline	4.6 (0.7)	4.6 (0.8)			
Total Cholostoro	Pre-pregnancy week 8	4.5 (0.7)	4.7 (0.8)	0.3	0.0 to 0.5	.027
mmol/I	Gestational week 12	4.4 (0.7)	4.4 (0.8)	0.0	-0.3 to 0.2	.811
	Gestational week 28	5.9 (1.2)	5.8 (1.1)	-0.1	-0.3 to 0.2	.574
LDL	Baseline	3.0 (0.9)	3.1 (0.8)			
cholesterol,	Pre-pregnancy week 8	2.9 (0.8)	3.1 (0.8)	0.2	0.0 to 0.4	.089
mmol/L	Gestational week 12	2.8 (0.7)	2.8 (0.8)	0.0	-0.3 to 0.2	.844

	Gestational week 28	3.9 (1.2)	3.9 (1.1)	-0.1	-0.4 to 0.1	.398
	Baseline	1.4 (0.3)	1.4 (0.3)			
HDL	Pre-pregnancy week 8	1.4 (0.3)	1.5 (0.3)	0.0	0.0 to 0.1	.376
cholesterol,	Gestational week 12	1.6 (0.4)	1.6 (0.2)	0.0	-0.1 to 0.1	.494
Thinks y E	Gestational week 28	1.8 (0.4)	1.8 (0.3)	0.0	-0.1 to 0.1	.816
	Baseline	1.0 (0.5)	0.9 (0.5)			
Triglycerides,	Pre-pregnancy week 8	1.0 (0.5)	0.9 (0.4)	0.0	-0.2 to 0.1	.826
mmol/L	Gestational week 12	1.1 (0.4)	1.1 (0.4)	0.0	-0.1 to 0.2	.545
	Gestational week 28	2.0 (0.7)	1.9 (0.6)	0.0	-0.2 to 0.1	.738
	Baseline	81.5 (13.2)	81.1 (16.0)			
	Pre-pregnancy week 8	81.6 (12.5)	78.9 (14.8)	-0.9	-2.0 to 0.3	.145
Weight, Kg	Gestational week 12	79.5 (12.9)	78.8 (15.2)	-0.9	-2.2 to 0.3	.152
	Gestational week 28	86.8 (12.3)	85.1 (15.4)	-2.0	-3.3 to -0.8	.002
	Baseline	31.6 (9.8)	30.8 (11.0)			
<b>F I</b>	Pre-pregnancy week 8	31.2 (9.5)	28.8 (9.7)	-0.8	-1.8 to 0.2	.103
Fat mass, kg	Gestational week 12	30.6 (9.5)	29.5 (10.7)	-0.5	-1.5 to 0.6	.410
	Gestational week 28	34.2 (9.0)	32.5 (10.8)	-1.5	-2.5 to -0.4	.008
	Baseline	37.9 (7.2)	37.0(7.6)			
Fat	Pre-pregnancy week 8	37.6 (7.0)	35.7 (6.6)	-0.6	-1.4 to 0.2	.144
percentage, %	Gestational week 12	37.7 (7.0)	36.5 (7.4)	-0.2	-1.0 to 0.7	.734
	Gestational week 28	38.8 (6.0)	37.4 (7.2)	-0.7	-1.5 to 0.2	.139
	Baseline	153.6 (52)	146 (57)			
Visceral fat	Pre-pregnancy week 8	151 (50)	135 (50)	-5.1	-10.9 to 0.7	.086
area, cm <sup>2</sup>	Gestational week 12	148 (51)	136 (54)	-2.3	-8.6 to 4.1	.483
	Gestational week 28	165 (47)	153 (54)	-6.2	-12.5 to 0.1	.054
	Baseline	27.7 (3.6)	27.9 (4.3)			
Muscle mass,	Pre-pregnancy week 8	28.0 (3.6)	27.8 (4.2)	0.0	-0.3 to 0.3	.855
kg	Gestational week 12	27.0 (3.2)	27.2 (4.1)	-0.2	-0.5 to 0.2	.316
	Gestational week 28	29.1 (3.1)	29.1 (4.2)	-0.3	-0.7 to 0.0	.061
	Baseline	94.5 (11.8)	93.0 (12.3)			
Waist	Pre-pregnancy week 8	93.9 (11.2)	92.0 (11.5)	-0.5	-2.9 to 1.8	.663
circumference,	Gestational week 12	95.1 (11.5)	94.9 (12.1)	0.6	-1.8 to 3.1	.610
cm	Gestational week 28	107.3 (8.4)	105.9 (10.6)	-1.5	-4.0 to 1.0	.243
	Baseline	121 (10)	118 (8)			
Systolic blood	Pre-pregnancy week 8	119 (8)	117 (8)	0.2	-2.4 to 2.7	.901
mmHg	Gestational week 12	114 (10)	110 (8)	-2.2	-5.0 to 0.6	.122
	Gestational week 28	110 (9)	110(11)	0.6	-2.3 to 3.4	.688
	Baseline	79 (7)	79 (6)			
Diastolic blood	Pre-pregnancy week 8	77 (6)	77 (6)	0.0	-2.1 to 2.0	.973
mmHg	Gestational week 12	71 (8)	70 (6)	-0.9	-3.1 to 1.3	.414
	Gestational week 28	69 (8)	70 (8)	0.5	-1.7 to 2.8	.647
Desting to 1	Baseline	72 (11)	71 (11)			
rate beats per	Pre-pregnancy week 8	69 (9)	67 (10)	-1.7	-4.8 to 1.4	.288
minute	Gestational week 12	71 (11)	69 (15)	-1.9	-5.4 to 1.5	.275
	Gestational week 28	78 (12)	77 (13)	-0.9	-4.3 to 2.6	.629

427 OGTT = Oral glucose tolerance test, HbA1c = Glycated haemoglobin, HOMA2-B = Homeostatic model 428 assessment of beta cell function, HOMA2-IR = Homeostatic model assessment of insulin resistance, HDL = 429 High-density lipoprotein cholesterol, LDL = Low-density lipoprotein cholesterol.

#### 430

#### 431 Adherence

432 At baseline, the average daily eating window for all participants was 11.9 (SD 1.7) hours. The 433 eating window was shorter in the intervention group during the rest of the study period, 434 compared with the control group (Figure 4). In the pre-pregnancy period, the intervention 435 group had an average eating window of 9.9 (SD 1.2) hours, which increased during 436 pregnancy (Figure 4 and Supplementary file 2). The intervention group significantly 437 increased their activity levels during the pre-pregnancy phase compared with baseline. The 438 average weekly PAI-points decreased throughout pregnancy and their physical activity levels 439 during pregnancy did not differ significantly from baseline (Figure 4 and Supplementary file 440 2).

- 441
- 442
- 443





445 Figure 4. Adherence to the intervention.

(A) Time-window of energy intake during the baseline week, pre-pregnancy period, and 1<sup>st</sup>, 2<sup>nd</sup>, and 3<sup>rd</sup> trimesters of pregnancy, according to group. The horizontal lines represent the daily duration of energy intake, with the left and right ends indicating means of the time of first and last energy intake for the intention-to-treat population. The *p*-values were calculated for a test of between-group differences in the window of energy intake, using linear mixed model. (B) Personal Activity Intelligence (PAI)-points earned per rolling week during baseline week, pre-pregnancy period, and first, second and third trimesters of pregnancy, in the intervention group. The bars show mean PAI-points per week, error bars show standard deviation, and

453 symbols show individual data. The *p*-values were calculated for within-group differences from baseline, 454 estimated by a linear mixed model.

455

#### 456 *Per protocol analyses*

In the per-protocol analyses, we included only the participants in the intervention group who obtained  $\geq$  75 weekly PAI-points and reported a  $\leq$  10-hour time window for energy intake on  $\geq$  2 out of 4 days in the handbook in the pre-pregnancy period. Thirty-one (37%) participants satisfied both criteria and were included in the analyses. The results from the per-protocol analyses were similar to those from the intention-to-treat analyses, except for time to pregnancy which was significantly longer in the intervention group (49 days, 95% CI 16 to 82, p = .004) (Supplementary File 3).

464

## 465 Dietary intake and physical activity

466 There was no statistically significant difference in self-reported total energy intake in the 467 intervention group compared with the control group pre-pregnancy (-57.0 kcal/day, 95% CI -468 183.9 to 69.9, p = .378) or during the first trimester (41.2 kcal/day, 95% CI -92.6 to 175.1, p = 469 .545), second trimester (39.7 kcal/day, 95% CI -101.4 to 180.9, p = .580), or third trimester 470 (-110.3 kcal/day, 95% Cl -248.0 to 27.3, p = .116). Nor were there any significant differences 471 in the distribution of macronutrients in the intervention group compared with the control 472 group before or during pregnancy (Supplementary file 2). Self-reported physical activity 473 level did not differ significantly between groups before or during pregnancy (Supplementary 474 file 2).

475

#### 476 Adverse events

477 No serious adverse events were reported during the study. Minor events included some 478 participants feeling dizzy and/or nauseous during fasting blood sampling and OGTT. Water 479 intake and fresh air solved this problem for most participants, although some discontinued 480 blood sampling. Some participants experienced local skin irritation from wearing a 481 continuous glucose monitor, requiring premature removal. Others reported local skin 482 irritation from the physical activity monitor armbands and smartwatches, which was 483 resolved by repositioning the monitors or switching to metal wristwatch armbands.

484

# 485 **Discussion**

### 486 Main findings

The BEFORE THE BEGINNING study is to our knowledge the first to implement a combination of TRE and exercise training before conception and throughout pregnancy in people at increased risk of developing GDM. Contrary to our hypothesis, we found no significant between-group differences in 2-hour plasma glucose level after a 75 g glucose load in gestational week 28, or in secondary outcome measures of glycaemic control at any time-points before or during pregnancy. Despite that the intervention reduced body weight and fat mass gain in gestational week 28, there was no significant effect on GDM incidence. The participants were able to adhere to the ≤ 10-hour TRE intervention pre-pregnancy, with a slight increase in the time-window of energy intake during pregnancy. While participants in the intervention group earned more than 100 PAI during pre-pregnancy, their activity levels declined during pregnancy, and there were no significant between-group differences in self-reported energy intake or physical activity throughout the study period.

499

## 500 Strengths and limitations

The main strengths of the BEFORE THE BEGINNING trial are the randomised controlled 501 502 design and longitudinal measurements throughout the pre-pregnancy and pregnancy 503 periods. The study had a high pregnancy rate (66% in both groups), and a low dropout rate 504 during pregnancy (7% in both groups). Still, the study has several limitations. Most 505 participants were highly educated, potentially resulting in healthy volunteer bias as they 506 were likely knowledgeable about their health and well-being.(44) Most of our participants 507 were also white and thus it is difficult to generalize our findings to other ethnicities. 508 However, recruitment via social media is thought to give a better representation of the 509 general population than other recruitment methods.(45) Since we had a low number of 510 participants (n = 3) with previous GDM, adjustment for stratification variable (GDM) was not 511 included in the analyses. Despite good adherence to TRE and exercise training in the pre-512 pregnancy period, we did not observe any improvements in cardiometabolic outcomes 513 compared with the control group. One possible reason for this could be the variable length 514 of the pre-pregnancy period, as the time to pregnancy varied greatly among participants. 515 Additionally, the number of PAI-points earned during the baseline week also varied greatly 516 within the participants in the intervention group and some of the participants had already a 517 high physical activity level at baseline. Self-reported activity levels did not differ significantly 518 between groups, suggesting that the level of physical activity in the control group was 519 similar as in the intervention group.

520

## 521 Comparisons with other studies

522 Most lifestyle interventions for GDM prevention begin during pregnancy, missing the crucial 523 window of opportunity in the pre-pregnancy period to improve cardiometabolic health 524 outcomes in at-risk individuals.(46) Systematic reviews and meta-analyses have highlighted 525 the lack of randomised controlled trials focusing on pre-pregnancy lifestyle interventions in 526 this population.(47,48) To date, only a handful of studies have investigated the role of prepregnancy lifestyle intervention continued throughout pregnancy on cardiometabolic 527 528 outcomes.(49–53) We found no significant effect of the intervention on glucose tolerance in 529 gestational week 28, or on any other glycaemic indices. In contrast to our hypothesis, we 530 estimated a higher mean 2-hour plasma glucose concentration in the intervention group in 531 gestational week 28 according to both the ITT and the per-protocol analysis (0.48 and 0.64 mmol/L, respectively), compared with the control group. However, the estimated mean 532 533 differences were smaller than what was considered a clinically relevant difference (1.0

534 mmol/L). A slight, non-significant, increase in 2-hour plasma glucose concentration (0.2 535 mmol/L) was also observed after a 5-week TRE intervention during pregnancy.(27)

536 In contrast to our findings, Price et al.(50) reported that a 12-week pre-pregnancy 537 very low-energy diet intervention significantly reduced 2-hour glucose during a 75 g OGTT 538 by 0.8 mmol/L compared with a standard diet intervention group among women with BMI 539 between 30 and 55 kg/m<sup>2</sup>. In that study, the participants in the intervention group consumed approximately 800 kcal/day for 12 weeks, followed by a maintenance period of 540 541 energy expenditure-matched energy intake throughout the pre-pregnancy period, while 542 also being advised to remain physically active (> 10,000 steps/day). The 12-week pre-543 pregnancy intervention induced a 9.2-kg weight loss compared with the standard diet, but 544 gestational weight gain remained unaffected.(50) Based on the findings form Price et al(50) 545 and our study, it seems likely to conclude that a pre-pregnancy intervention must induce a 546 substantial weight loss to impact glucose tolerance in pregnancy. Our trial, along with 547 others(49–51,53), did not find any significant effect of pre-pregnancy lifestyle interventions 548 on GDM incidence in gestational week 28. Despite being at higher risk of GDM, with 86% of the participants having BMI above 25 kg/m<sup>2</sup> and 27% having a family history of diabetes, 549 only 12% of our participants were diagnosed with GDM in gestational week 28. The GDM 550 551 incidence in our trial was substantially lower than in the RADIEL study (60% in the control 552 group and 54% in the intervention group)(49) and in the study by Phelan et al. (40% in the 553 control group and 25% in the intervention group).(53) The low incidence of GDM observed 554 in our study may be attributed to the high education level (87%) and mostly white 555 participants (89%)(54). Importantly, all our participants included in the analyses were 556 normoglycaemic at baseline, which may help explain the lack of effect since individuals with 557 impaired glucose metabolism benefit the most from TRE.(55)

The intervention group had significantly lower body weight gain (2.0 kg) in 558 559 gestational week 28, compared with the control group, but there were no significant 560 differences between groups in the pre-pregnancy period or the first trimester of pregnancy. 561 In contrast, some of the previous pre-pregnancy lifestyle interventions induced pre-562 pregnancy weight loss, but did not affect weight gain during pregnancy. (49,50,52,53) In the 563 PREPARE study, the intervention group lost weight before pregnancy, followed by a greater 564 weight gain in late pregnancy.(52) The addition of exercise training to the TRE intervention 565 in our study may have prevented lean mass loss which is common in TRE interventions.(25) 566 Although not statistically significant, the estimated mean visceral fat area was lower in the 567 intervention group compared with the control group both before and during pregnancy. The 568 amount of visceral fat in early pregnancy has been shown to better predict GDM than prepregnancy BMI.(56) However, the observed changes in body composition may not have 569 570 been large enough to improve the other cardiometabolic outcomes in our study.

571 There were no significant between-group differences in total energy intake or 572 macronutrient distribution before or during pregnancy, which probably partly explain the 573 neutral effect of the intervention on most outcome measures. In contrast, Haganes et 574 al.(23) reported that 7 weeks of combined TRE and HIIT induced a reduction in energy intake 575 of approximately 200 kcal/day compared with the control group, along with improvements 576 in several cardiometabolic outcomes, among reproductive-aged women with 577 overweight/obesity. Correspondingly, the combination of TRE and high-intensity functional 578 training for 12 weeks resulted in a 175 kcal/day reduction in total energy intake among 579 women with obesity.(57) In BEFORE THE BEGINNING, we chose a modified TRE regimen, 580 allowing for unrestricted intake on 2 days per week. Even if such a regimen allows for more 581 flexibility and potentially improved long-term adherence than a stricter TRE intervention, our TRE intervention was not sufficiently potent to reduce energy intake. Participants in 582 583 dietary interventions often underreport their total energy intake(58), including when using 584 the electronic application that we used.(59) Still, there is no reason to believe that such 585 under-reporting would be different between the intervention and control group.

586 There is thus far little research on the safety and acceptability of TRE during 587 pregnancy, and only one previous randomised controlled trial on the effects of TRE on 588 glycaemic control.(27) In a recent online survey study, only around half of the participants 589 agreed that a TRE pattern is safe during pregnancy and 23.7% would be willing to try TRE 590 during pregnancy to improve their health.(60) There was a gradual decrease in the 591 adherence to TRE in our study, from pre-pregnancy and throughout pregnancy. In our 592 previous study of TRE in pregnancy,(27) the participants could adhere to a 10-hour TRE 593 intervention on  $\sim$  5 days/week for 5 weeks in the second or third trimester of pregnancy. 594 However, in that study, the trial period was markedly shorter, and the participants were 595 already pregnant at inclusion, thus likely less bothered by nausea and other barriers to TRE 596 than in the BEFORE THE BEGINNING study. Collectively, the experimental evidence to date 597 on TRE during pregnancy indicates that there is no positive effect on maternal glycaemic 598 control.

599 HIIT is now considered safe and feasible during pregnancy.(29-31) However, the 600 long-term adherence to HIIT interventions during pregnancy remains to be explored. In our 601 study, the participants in the intervention group significantly increased their physical activity 602 levels in the pre-pregnancy period with a decrease during pregnancy, suggesting suboptimal 603 adherence to the exercise component of the intervention. Only 43% of the participants in 604 the intervention group met the goal of 100 weekly PAI-points pre-pregnancy, decreasing 605 gradually to 10% of participants during the third trimester. Although self-reported physical 606 activity levels did not differ significantly between the groups, the reported physical activity 607 levels were higher in the intervention group throughout the study. Adherence to exercise 608 training is typically lower in unsupervised compared with supervised situations. (61) The 609 declining adherence to exercise during the study period was likely due to a combination of 610 the unsupervised nature of the intervention, pregnancy-related side effects (e.g., nausea, 611 pelvic pain), and decreasing motivation over a long study period. Overall, adherence to 612 lifestyle interventions in pregnancy remains a significant challenge, especially in real-life 613 settings without close supervision.

614

#### 615 Conclusion and implications for clinicians and policymakers

The combination of TRE and exercise training, initiated before and continued throughout pregnancy, had limited effects on glucose tolerance in late pregnancy among people with an increased risk of GDM. Despite the challenges with adherence to the intervention, the intervention group had lower weight and fat mass gain in gestational week 28. Emerging evidence highlights that the pre-pregnancy period is an ideal time to intervene in people at high risk of cardiometabolic diseases and it is critical to find optimal strategies to improve adherence to lifestyle interventions in this population.

623

## 624 Unanswered questions and future research

625 We experienced challenges with adherences to the intervention, particularly to the exercise 626 training component in pregnancy. Future studies should assess whether more organised 627 high-intensity exercise training during pregnancy lead to better long-term exercise 628 adherence. Using more interactive digital health technology (e.g., smartphone apps, 629 automatically delivered daily reminders, weekly goals) should also be explored. The per-630 protocol analysis indicated longer time to pregnancy in the intervention group, which should 631 be further investigated. Not all participants in our study had high BMI (some were included 632 based on the other risk factors), and therefore, there were variations in body composition 633 and cardiometabolic markers. Future studies should also determine whether interventions 634 based on single risk factors (e.g., high BMI, previous GDM) to avoid large within-group 635 variations, lead to better cardiometabolic outcomes.

636

## 637 What is already known on this topic

- High pre-pregnancy BMI and excessive gestational weight gain are associated with a
   greater risk of developing GDM and adverse pregnancy and neonatal outcomes.
- 640 Systematic reviews and meta-analyses suggest that pre-pregnancy lifestyle
   641 interventions are necessary to improve maternal and fetal cardiometabolic
   642 outcomes.
- Existing guidelines on diet and physical activity for pregnant individuals are
   insufficient to achieve clinically significant cardiometabolic benefits.
- 645

#### 646 What this study adds

- The BEFORE THE BEGINNING trial is the first trial to investigate the effect of
   combined TRE and exercise training before and during pregnancy in people at high
   risk of GDM.
- 650 The intervention did not result in significantly improved glycaemic outcomes.
- 651 There was some evidence of lower weight and fat mass gain in gestational week 28
  652 in the intervention group compared with the control group.

654 **Ethical approval:** The Regional Committees for Medical and Health Research Ethics in 655 Norway approved the study (REK 143756).

656

657 Data availability statement: Data reported in this paper can be shared by the corresponding658 author upon request.

659

Acknowledgements: We are thankful to all the participants for their valuable contributions. NeXt Move, Norwegian University of Science and Technology (NTNU) provided the equipment and lab facilities for cardiorespiratory fitness testing, and the clinical measurements are obtained at the Clinical Research Facility, St. Olavs Hospital. We used eFORSK, a stand-alone form-based information and communications technology solution for electronic data collection, developed by Central Norway Regional Health Authority for sending invitations to the study.

667

Footnotes: TM, KÅS, TF, and SLF conceived and contributed to the study design and data analysis plans. GR, MAJS, and HMSS coordinated the study, performed measurements, monitored participants, and supervised the exercise training. MAJS and HMSS drafted the manuscript with equal contribution. All authors provided feedback and approved the final manuscript.

673

Funding: The trial is funded by the Novo Nordisk Foundation (NNF19SA058975), The Liaison
Committee for education, research, and innovation in Central Norway, and The Joint
Research Committee between St. Olavs Hospital and the Faculty of Medicine and Health
Sciences, NTNU (FFU). The sponsors have no role in study design, data collection, analysis,
and publication of results.

679

680 **Declaration of interests:** The authors declare that they have no competing interests.

681

Transparency: The authors confirm that this manuscript is an honest, accurate, and
transparent account of the study being reported; that no important aspects of the study

have been omitted; and that any discrepancies from the study as planned and registered

685 have been explained.

686

**Dissemination to participants and related patient and public communities:** We plan to disseminate all the results to study participants and patient organisations as soon as the study is published. The result of this trial will be presented at relevant national and international conferences.

691

## 692 Reference

International Diabetes Federation, Brussels, Belgium. IDF Diabetes Atlas 2021 10th
 edition [Internet]. 2021. Available from: https://diabetesatlas.org/atlas/tenth-edition/

- Angueira AR, Ludvik AE, Reddy TE, Wicksteed B, William L Lowe J, Layden BT. New
  Insights Into Gestational Glucose Metabolism: Lessons Learned From 21st Century
  Approaches. Diabetes. 2015 Jan 13;64(2):327.
- Syndrome: A Review of the Associations and Recommendations. Endocr Pract. 2024 Jan 1;30(1):78–82.
- Yu Y, Soohoo M, Sørensen HT, Li J, Arah OA. Gestational Diabetes Mellitus and the
   Risks of Overall and Type-Specific Cardiovascular Diseases: A Population- and Sibling Matched Cohort Study. Diabetes Care. 2022 Jan 1;45(1):151–9.
- 7045.Hahn S, Körber S, Gerber B, Stubert J. Prediction of recurrent gestational diabetes705mellitus: a retrospective cohort study. Arch Gynecol Obstet. 2023 Mar 1;307(3):689–97.
- Vounzoulaki E, Khunti K, Abner SC, Tan BK, Davies MJ, Gillies CL. Progression to type
  2 diabetes in women with a known history of gestational diabetes: systematic review and
  meta-analysis. BMJ. 2020 May 13;369:m1361.
- 709 7. Lowe WL, Lowe LP, Kuang A, Catalano PM, Nodzenski M, Talbot O, et al. Maternal
  710 glucose levels during pregnancy and childhood adiposity in the Hyperglycemia and
  711 Adverse Pregnancy Outcome Follow-up Study. Diabetologia. 2019 Apr;62(4):598–610.
- 8. Mantzorou M, Papandreou D, Pavlidou E, Papadopoulou SK, Tolia M, Mentzelou M,
  et al. Maternal Gestational Diabetes Is Associated with High Risk of Childhood Overweight
  and Obesity: A Cross-Sectional Study in Pre-School Children Aged 2–5 Years. Medicina
  (Mex). 2023 Feb 24;59(3):455.
- 9. Blotsky AL, Rahme E, Dahhou M, Nakhla M, Dasgupta K. Gestational diabetes
  associated with incident diabetes in childhood and youth: a retrospective cohort study.
  CMAJ. 2019 Apr 15;191(15):E410–7.
- Holder T, Giannini C, Santoro N, Pierpont B, Shaw M, Duran E, et al. A low disposition
  index in adolescent offspring of mothers with gestational diabetes: a risk marker for the
  development of impaired glucose tolerance in youth. Diabetologia. 2014 Nov
  1;57(11):2413-20.
- 11. Clausen TD, Mathiesen ER, Hansen T, Pedersen O, Jensen DM, Lauenborg J, et al.
  High Prevalence of Type 2 Diabetes and Pre-Diabetes in Adult Offspring of Women With
  Gestational Diabetes Mellitus or Type 1 Diabetes: The role of intrauterine hyperglycemia.
  Diabetes Care. 2008 Feb 1;31(2):340–6.

72712.American Diabetes Association. Diabetes Care. 2017 [cited 2024 Mar 13].728Management of Diabetes in Pregnancy. Available from:729https://diabetesjournals.org/care/article/40/Supplement\_1/S114/36877/13-

730 Management-of-Diabetes-in-Pregnancy

731 13. Peña A, Miller AM, Campbell AG, Holden RJ, Scifres CM. Mapping Lifestyle 732 Interventions for Gestational Diabetes Prevention: A Scoping Review. Curr Diab Rep 733 [Internet]. 2024 Feb 17 cited 2024 Mar 13]; Available from: 734 https://doi.org/10.1007/s11892-024-01535-5

- 735 14. Phelan S. Windows of Opportunity for Lifestyle Interventions to Prevent Gestational
  736 Diabetes Mellitus. Am J Perinatol. 2016 Nov;33(13):1291–9.
- 15. Cha E, Smart MJ, Braxter BJ, Faulkner MS. Preconception Care to Reduce the Risks of
  Overweight and Obesity in Women of Reproductive Age: An Integrative Review. Int J
  Environ Res Public Health. 2021 Apr 26;18(9):4582.
- T40 16. Sparks JR, Ghildayal N, Hivert MF, Redman LM. Lifestyle interventions in pregnancy
   T41 targeting GDM prevention: looking ahead to precision medicine. Diabetologia. 2022
   T42 Nov;65(11):1814-24.
- 74317.Gaston A, Cramp A. Exercise during pregnancy: A review of patterns and744determinants. J Sci Med Sport. 2011 Jul 1;14(4):299–305.
- Tobias DK, Zhang C, Chavarro J, Bowers K, Rich-Edwards J, Rosner B, et al.
  Prepregnancy adherence to dietary patterns and lower risk of gestational diabetes
  mellitus123. Am J Clin Nutr. 2012 Aug 1;96(2):289–95.
- 19. Sampathkumar S, Parkhi D, Ghebremichael-Weldeselassie Y, Sukumar N, Saravanan
  P. Effectiveness of pre-pregnancy lifestyle in preventing gestational diabetes mellitus—a
  systematic review and meta-analysis of 257,876 pregnancies. Nutr Diabetes. 2023 Nov
  16;13:22.
- Raab R, Michel S, Günther J, Hoffmann J, Stecher L, Hauner H. Associations between
  lifestyle interventions during pregnancy and childhood weight and growth: a systematic
  review and meta-analysis. Int J Behav Nutr Phys Act. 2021 Jan 7;18(1):8.
- Lim S, Takele WW, Vesco KK, Redman LM, Hannah W, Bonham MP, et al. Participant
  characteristics in the prevention of gestational diabetes as evidence for precision
  medicine: a systematic review and meta-analysis. Commun Med. 2023 Oct 5;3:137.
- Che T, Yan C, Tian D, Zhang X, Liu X, Wu Z. Time-restricted feeding improves blood
  glucose and insulin sensitivity in overweight patients with type 2 diabetes: a randomised
  controlled trial. Nutr Metab. 2021 Oct 7;18(1):88.
- Haganes KL, Silva CP, Eyjólfsdóttir SK, Steen S, Grindberg M, Lydersen S, et al. Timerestricted eating and exercise training improve HbA1c and body composition in women
  with overweight/obesity: A randomized controlled trial. Cell Metab. 2022 Oct
  4;34(10):1457-1471.e4.
- 765 24. Khalafi M, Ravasi AA, Malandish A, Rosenkranz SK. The impact of high-intensity
  766 interval training on postprandial glucose and insulin: A systematic review and *meta*767 analysis. Diabetes Res Clin Pract. 2022 Apr 1;186:109815.
- 768 25. Kotarsky CJ, Johnson NR, Mahoney SJ, Mitchell SL, Schimek RL, Stastny SN, et al.
  769 Time-restricted eating and concurrent exercise training reduces fat mass and increases
  770 lean mass in overweight and obese adults. Physiol Rep. 2021 May;9(10):e14868.
- Wilkinson MJ, Manoogian ENC, Zadourian A, Lo H, Fakhouri S, Shoghi A, et al. Tenhour time-restricted eating reduces weight, blood pressure, and atherogenic lipids in
  patients with metabolic syndrome. Cell Metab. 2020 Jan 7;31(1):92-104.e5.

27. Skarstad HMS, Haganes KL, Sujan MAJ, Gellein TM, Johansen MK, Salvesen KÅ, et al.
A randomized feasibility trial of time-restricted eating during pregnancy in people with
increased risk of gestational diabetes. Sci Rep. 2024 Sep 28;14(1):22476.

28. Loy SL, Chan JKY, Wee PH, Colega MT, Cheung YB, Godfrey KM, et al. Maternal
Circadian Eating Time and Frequency Are Associated with Blood Glucose Concentrations
during Pregnancy. J Nutr. 2017 Jan;147(1):70–7.

- Anderson J, Pudwell J, McAuslan C, Barr L, Kehoe J, Davies GA. Acute fetal response
  to high-intensity interval training in the second and third trimesters of pregnancy. Appl
  Physiol Nutr Metab. 2021 Dec;46(12):1552–8.
- 30. Beetham KS, Giles C, Noetel M, Clifton V, Jones JC, Naughton G. The effects of
  vigorous intensity exercise in the third trimester of pregnancy: a systematic review and
  meta-analysis. BMC Pregnancy Childbirth. 2019 Aug 7;19(1):281.
- 31. Wowdzia JB, Hazell TJ, Davenport MH. Glycemic response to acute high-intensity
  interval versus moderate-intensity continuous exercise during pregnancy. Physiol Rep.
  2022 Sep;10(18):e15454.
- Sujan MAJ, Skarstad HMS, Rosvold G, Fougner SL, Nyrnes SA, Iversen AC, et al.
  Randomised controlled trial of preconception lifestyle intervention on maternal and
  offspring health in people with increased risk of gestational diabetes: study protocol for
  the BEFORE THE BEGINNING trial. BMJ Open. 2023 Oct 4;13(10):e073572.
- Nes BM, Gutvik CR, Lavie CJ, Nauman J, Wisløff U. Personalized Activity Intelligence
  (PAI) for Prevention of Cardiovascular Disease and Promotion of Physical Activity. Am J
  Med. 2017 Mar 1;130(3):328–36.
- Zisko N, Skjerve KN, Tari AR, Sandbakk SB, Wisløff U, Nes BM, et al. Personal Activity
  Intelligence (PAI), Sedentary Behavior and Cardiovascular Risk Factor Clustering the
  HUNT Study. Prog Cardiovasc Dis. 2017 Jul 1;60(1):89–95.
- World Health Organization. Diagnostic criteria and classification of hyperglycaemia
   first detected in pregnancy. World Health Organization; 2013.

801 36. Floch JPL, Escuyer P, Baudin E, Baudon D, Perlemuter L. Blood Glucose Area Under
802 the Curve: Methodological Aspects. Diabetes Care. 1990 Feb 1;13(2):172–5.

- 37. Wallace TM, Levy JC, Matthews DR. Use and Abuse of HOMA Modeling. Diabetes
  Care. 2004 Jun 1;27(6):1487–95.
- 38. Gutt M, Davis CL, Spitzer SB, Llabre MM, Kumar M, Czarnecki EM, et al. Validation of
  the insulin sensitivity index (ISI(0,120)): comparison with other measures. Diabetes Res
  Clin Pract. 2000 Mar;47(3):177–84.
- 808 39. Phillips DI, Clark PM, Hales CN, Osmond C. Understanding oral glucose tolerance:
  809 comparison of glucose or insulin measurements during the oral glucose tolerance test
  810 with specific measurements of insulin resistance and insulin secretion. Diabet Med J Br
  811 Diabet Assoc. 1994 Apr;11(3):286–92.
- 812 40. Stumvoll M, Mitrakou A, Pimenta W, Jenssen T, Yki-Järvinen H, Van Haeften T, et al.
  813 Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity.
  814 Diabetes Care. 2000 Mar;23(3):295–301.
- 41. Craig CL, Marshall AL, Sjöström M, Bauman AE, Booth ML, Ainsworth BE, et al.
  International physical activity questionnaire: 12-country reliability and validity. Med Sci
  Sports Exerc. 2003 Aug;35(8):1381–95.
- Mikkelsen EM, Riis AH, Wise LA, Hatch EE, Rothman KJ, Sørensen HT. Pre-gravid oral
  contraceptive use and time to pregnancy: a Danish prospective cohort study. Hum
  Reprod Oxf Engl. 2013 May;28(5):1398–405.

- 43. J T, L B, T H, J R, M W, M H. Different ways to estimate treatment effects in
  randomised controlled trials. Contemp Clin Trials Commun. 2018 Jun;10:80–5.
- 44. Brayne C, Moffitt TE. The limitations of large-scale volunteer databases to address
  inequalities and global challenges in health and aging. Nat Aging. 2022 Sep;2(9):775–83.
- 825 45. Whitaker C, Stevelink S, Fear N. The Use of Facebook in Recruiting Participants for
- 826Health Research Purposes: A Systematic Review. J Med Internet Res. 2017 Aug82728;19(8):e290.
- 46. Phelan S. Windows of Opportunity for Lifestyle Interventions to Prevent Gestational
  Diabetes Mellitus. Am J Perinatol. 2016 Nov;33(13):1291–9.
- 47. Takele WW, Vesco KK, Josefson J, Redman LM, Hannah W, Bonham MP, et al.
  Effective interventions in preventing gestational diabetes mellitus: A systematic review
  and meta-analysis. Commun Med. 2024 Apr 20;4(1):1–15.
- 48. Quotah OF, Andreeva D, Nowak KG, Dalrymple KV, Almubarak A, Patel A, et al.
  Interventions in preconception and pregnant women at risk of gestational diabetes; a
  systematic review and meta-analysis of randomised controlled trials. Diabetol Metab
  Syndr. 2024 Jan 4;16(1):8.
- Rönö K, Stach-Lempinen B, Eriksson JG, Pöyhönen-Alho M, Klemetti MM, Roine RP,
  et al. Prevention of gestational diabetes with a prepregnancy lifestyle intervention findings from a randomized controlled trial. Int J Womens Health. 2018;10:493–501.
- Price SAL, Sumithran P, Nankervis AJ, Permezel M, Prendergast LA, Proietto J. Impact
  of preconception weight loss on fasting glucose and pregnancy outcomes in women with
  obesity: A randomized trial. Obesity. 2021;29(9):1445–57.
- LeBlanc ES, Smith NX, Vesco KK, Hillier TA, Stevens VJ. Weight Loss Prior to
  Pregnancy and Early Gestational Glycemia: Prepare, a Randomized Clinical Trial. J Clin
  Endocrinol Metab. 2021 Nov 19;106(12):e5001–10.
- LeBlanc ES, Smith NX, Vesco KK, Paul IM, Stevens VJ. Weight loss prior to pregnancy
  and subsequent gestational weight gain: Prepare, a randomized clinical trial. Am J Obstet
  Gynecol. 2021 Jan;224(1):99.e1-99.e14.
- 849 53. Phelan S, Jelalian E, Coustan D, Caughey AB, Castorino K, Hagobian T, et al.
  850 Randomized controlled trial of prepregnancy lifestyle intervention to reduce recurrence
  851 of gestational diabetes mellitus. Am J Obstet Gynecol. 2023 Aug 1;229(2):158.e1-158.e14.
- Waage CW, Toftemo I, Brænd AM, Sletner L, Sommer C, Birkeland KI, et al. Cohort
  profile update: the Norwegian STORK Groruddalen (STORK G) pregnancy and birth
  cohort—the role of ethnicity and causal pathways for obesity, type 2 diabetes,
  cardiovascular disease and other health issues. BMJ Open. 2023 Oct 1;13(10):e076251.
- 856 55. Kang J, Ratamess NA, Faigenbaum AD, Bush JA, Beller N, Vargas A, et al. Effect of
  857 Time-Restricted Feeding on Anthropometric, Metabolic, and Fitness Parameters: A
  858 Systematic Review. J Am Nutr Assoc. 2022;41(8):810–25.
- 859 56. Alves JG, Souza ASR, Figueiroa JN, Araújo CAL de, Guimarães A, Ray JG. Visceral
  860 Adipose Tissue Depth in Early Pregnancy and Gestational Diabetes Mellitus a Cohort
  861 Study. Sci Rep. 2020 Feb 6;10:2032.
- 57. Ameur R, Maaloul R, Tagougui S, Neffati F, Kacem FH, Najjar MF, et al. Unlocking the
  power of synergy: High-intensity functional training and early time-restricted eating for
  transformative changes in body composition and cardiometabolic health in inactive
  women with obesity. PLOS ONE. 2024 May 1;19(5):e0301369.
- 866 58. Park Y, Dodd KW, Kipnis V, Thompson FE, Potischman N, Schoeller DA, et al.
  867 Comparison of self-reported dietary intakes from the Automated Self-Administered 24-h

- recall, 4-d food records, and food-frequency questionnaires against recovery biomarkers.
  Am J Clin Nutr. 2018 Jan 1;107(1):80–93.
- Tosi M, Radice D, Carioni G, Vecchiati T, Fiori F, Parpinel M, et al. Accuracy of
  applications to monitor food intake: Evaluation by comparison with 3-d food diary. Nutr
  Burbank Los Angel Cty Calif. 2021 Apr;84:111018.
- Flanagan EW, Kebbe M, Sparks JR, Redman LM. Assessment of Eating Behaviors and
  Perceptions of Time-Restricted Eating During Pregnancy. J Nutr. 2022 Feb 1;152(2):475–
  83.
- 876 61. Santos A, Braaten K, MacPherson M, Vasconcellos D, Vis-Dunbar M, Lonsdale C, et al.
  877 Rates of compliance and adherence to high-intensity interval training: a systematic
  878 review and Meta-analyses. Int J Behav Nutr Phys Act. 2023 Nov 21;20(1):134.
- 879
- 880
- 881